Growth Metrics

Caribou Biosciences (CRBU) Non-Current Deferred Tax Liability (2020 - 2025)

Caribou Biosciences has reported Non-Current Deferred Tax Liability over the past 6 years, most recently at $548000.0 for Q3 2025.

  • Quarterly Non-Current Deferred Tax Liability fell 1.62% to $548000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $548000.0 through Sep 2025, down 1.62% year-over-year, with the annual reading at $548000.0 for FY2024, 1.62% down from the prior year.
  • Non-Current Deferred Tax Liability was $548000.0 for Q3 2025 at Caribou Biosciences, roughly flat from $548000.0 in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $10.9 million in Q4 2022 and troughed at $155000.0 in Q2 2021.
  • The 5-year median for Non-Current Deferred Tax Liability is $512000.0 (2021), against an average of $1.0 million.
  • Year-over-year, Non-Current Deferred Tax Liability surged 2186.55% in 2022 and then tumbled 94.88% in 2023.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $476000.0 in 2021, then surged by 2186.55% to $10.9 million in 2022, then tumbled by 94.88% to $557000.0 in 2023, then fell by 1.62% to $548000.0 in 2024, then changed by 0.0% to $548000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Non-Current Deferred Tax Liability are $548000.0 (Q3 2025), $548000.0 (Q2 2025), and $548000.0 (Q1 2025).